Charles Quick
Concepts (394)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Endometrial Neoplasms | 18 | 2021 | 144 | 4.720 |
Why?
| Carcinoma in Situ | 7 | 2022 | 74 | 2.060 |
Why?
| Uterine Neoplasms | 10 | 2023 | 63 | 2.050 |
Why?
| Vulvar Neoplasms | 5 | 2022 | 54 | 1.990 |
Why?
| Carcinoma, Endometrioid | 6 | 2021 | 41 | 1.700 |
Why?
| PAX2 Transcription Factor | 7 | 2015 | 22 | 1.520 |
Why?
| Carcinoma, Squamous Cell | 8 | 2019 | 384 | 1.470 |
Why?
| Adenocarcinoma | 9 | 2019 | 428 | 1.440 |
Why?
| Endometrial Hyperplasia | 4 | 2019 | 14 | 1.200 |
Why?
| Stromal Cells | 2 | 2016 | 79 | 1.080 |
Why?
| Uterine Cervical Neoplasms | 6 | 2021 | 276 | 1.050 |
Why?
| Ovarian Neoplasms | 9 | 2018 | 472 | 1.030 |
Why?
| Sarcoma, Alveolar Soft Part | 1 | 2023 | 1 | 0.950 |
Why?
| Myometrium | 2 | 2013 | 15 | 0.900 |
Why?
| Endometrium | 6 | 2023 | 43 | 0.870 |
Why?
| Female | 63 | 2024 | 28441 | 0.850 |
Why?
| Adenocarcinoma, Clear Cell | 6 | 2019 | 37 | 0.820 |
Why?
| Precancerous Conditions | 3 | 2019 | 93 | 0.790 |
Why?
| Cystadenocarcinoma, Serous | 4 | 2013 | 74 | 0.720 |
Why?
| Aged, 80 and over | 19 | 2021 | 3431 | 0.700 |
Why?
| Cannabidiol | 4 | 2020 | 35 | 0.690 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2017 | 250 | 0.670 |
Why?
| Peripheral Nerves | 2 | 2015 | 51 | 0.660 |
Why?
| Middle Aged | 33 | 2021 | 13088 | 0.620 |
Why?
| Humans | 65 | 2023 | 54284 | 0.610 |
Why?
| Placenta | 6 | 2021 | 135 | 0.600 |
Why?
| Epithelial-Mesenchymal Transition | 2 | 2016 | 53 | 0.590 |
Why?
| Cervix Uteri | 2 | 2017 | 53 | 0.590 |
Why?
| Aged | 28 | 2021 | 10054 | 0.580 |
Why?
| Adenosarcoma | 1 | 2016 | 3 | 0.580 |
Why?
| Immunohistochemistry | 15 | 2020 | 1089 | 0.570 |
Why?
| Polyps | 1 | 2016 | 19 | 0.560 |
Why?
| Adult | 30 | 2021 | 14207 | 0.550 |
Why?
| Uterine Cervical Dysplasia | 1 | 2016 | 51 | 0.550 |
Why?
| Mutation | 8 | 2021 | 1501 | 0.550 |
Why?
| Tumor Microenvironment | 4 | 2021 | 209 | 0.540 |
Why?
| Fallopian Tubes | 2 | 2012 | 25 | 0.530 |
Why?
| Fibroma | 1 | 2015 | 41 | 0.530 |
Why?
| Lymphatic Metastasis | 6 | 2019 | 256 | 0.520 |
Why?
| Plant Extracts | 4 | 2020 | 193 | 0.500 |
Why?
| Neoplasm Staging | 8 | 2019 | 806 | 0.470 |
Why?
| Neoplasm Invasiveness | 6 | 2019 | 295 | 0.460 |
Why?
| Prognosis | 10 | 2021 | 2118 | 0.420 |
Why?
| Pelvic Neoplasms | 1 | 2011 | 20 | 0.410 |
Why?
| Uterus | 3 | 2023 | 98 | 0.410 |
Why?
| Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 74 | 0.400 |
Why?
| Ejaculatory Ducts | 1 | 2010 | 3 | 0.380 |
Why?
| Seminal Vesicles | 1 | 2010 | 12 | 0.380 |
Why?
| Cannabis | 4 | 2020 | 147 | 0.370 |
Why?
| Neoplasm Recurrence, Local | 4 | 2015 | 644 | 0.370 |
Why?
| Spectrum Analysis, Raman | 2 | 2021 | 68 | 0.370 |
Why?
| Prostate | 1 | 2010 | 117 | 0.350 |
Why?
| Bromcresol Purple | 1 | 2009 | 4 | 0.350 |
Why?
| Electrophoresis, Capillary | 1 | 2009 | 16 | 0.350 |
Why?
| Serum Albumin | 1 | 2009 | 62 | 0.340 |
Why?
| Human papillomavirus 16 | 2 | 2021 | 48 | 0.330 |
Why?
| beta Catenin | 2 | 2021 | 102 | 0.330 |
Why?
| Methionine | 2 | 2020 | 146 | 0.320 |
Why?
| Disease Progression | 4 | 2020 | 913 | 0.320 |
Why?
| Papillomavirus Infections | 2 | 2022 | 163 | 0.310 |
Why?
| Genital Neoplasms, Female | 2 | 2018 | 38 | 0.310 |
Why?
| Papillomavirus Vaccines | 2 | 2021 | 68 | 0.310 |
Why?
| Diabetes Mellitus | 2 | 2023 | 309 | 0.310 |
Why?
| Anus Neoplasms | 2 | 2018 | 33 | 0.310 |
Why?
| Metaplasia | 2 | 2019 | 20 | 0.300 |
Why?
| Cell Proliferation | 4 | 2021 | 1096 | 0.290 |
Why?
| Antigens, CD | 2 | 2019 | 242 | 0.290 |
Why?
| Diagnosis, Differential | 8 | 2020 | 1136 | 0.280 |
Why?
| Colitis | 2 | 2020 | 52 | 0.280 |
Why?
| Prostatic Neoplasms | 1 | 2010 | 415 | 0.280 |
Why?
| Polyethylene Glycols | 2 | 2017 | 106 | 0.270 |
Why?
| Neoplasm Grading | 5 | 2021 | 131 | 0.270 |
Why?
| Mice | 14 | 2024 | 6413 | 0.270 |
Why?
| Melanoma | 2 | 2020 | 313 | 0.270 |
Why?
| Hypertension | 2 | 2021 | 564 | 0.260 |
Why?
| Chi-Square Distribution | 2 | 2016 | 318 | 0.260 |
Why?
| Gold | 2 | 2017 | 164 | 0.260 |
Why?
| Proteomics | 3 | 2017 | 343 | 0.250 |
Why?
| Aspartic Acid Endopeptidases | 2 | 2015 | 17 | 0.250 |
Why?
| Nanoparticles | 2 | 2017 | 173 | 0.250 |
Why?
| Racemases and Epimerases | 2 | 2015 | 15 | 0.250 |
Why?
| Retrospective Studies | 11 | 2020 | 6432 | 0.240 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2024 | 44 | 0.230 |
Why?
| Homeodomain Proteins | 1 | 2024 | 82 | 0.230 |
Why?
| Head and Neck Neoplasms | 2 | 2019 | 335 | 0.230 |
Why?
| Chlamydia muridarum | 1 | 2024 | 53 | 0.230 |
Why?
| Kidney Neoplasms | 2 | 2018 | 196 | 0.230 |
Why?
| Endometriosis | 1 | 2023 | 16 | 0.230 |
Why?
| Lung Neoplasms | 2 | 2019 | 642 | 0.230 |
Why?
| Gynecology | 2 | 2020 | 50 | 0.220 |
Why?
| Adenocarcinoma, Sebaceous | 1 | 2022 | 6 | 0.220 |
Why?
| Sebaceous Gland Neoplasms | 1 | 2022 | 15 | 0.220 |
Why?
| Observer Variation | 3 | 2017 | 138 | 0.220 |
Why?
| Young Adult | 6 | 2020 | 4318 | 0.210 |
Why?
| Chlamydia Infections | 1 | 2024 | 119 | 0.210 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2024 | 180 | 0.210 |
Why?
| Fallopian Tube Neoplasms | 2 | 2012 | 19 | 0.210 |
Why?
| Gestational Trophoblastic Disease | 2 | 2012 | 2 | 0.210 |
Why?
| Animals | 15 | 2024 | 14385 | 0.210 |
Why?
| Immunotherapy | 2 | 2021 | 263 | 0.210 |
Why?
| CTLA-4 Antigen | 1 | 2021 | 29 | 0.210 |
Why?
| Oncogene Fusion | 1 | 2021 | 4 | 0.200 |
Why?
| Fetal Membranes, Premature Rupture | 1 | 2021 | 23 | 0.200 |
Why?
| Genotype | 2 | 2021 | 599 | 0.200 |
Why?
| PTEN Phosphohydrolase | 3 | 2020 | 61 | 0.200 |
Why?
| Estrogens | 2 | 2023 | 244 | 0.200 |
Why?
| Leiomyosarcoma | 1 | 2021 | 25 | 0.200 |
Why?
| Diabetes, Gestational | 1 | 2021 | 54 | 0.190 |
Why?
| Transcription Factors | 3 | 2020 | 622 | 0.190 |
Why?
| Carcinosarcoma | 2 | 2017 | 18 | 0.190 |
Why?
| Cancer Vaccines | 1 | 2021 | 103 | 0.190 |
Why?
| Infant, Small for Gestational Age | 1 | 2020 | 34 | 0.190 |
Why?
| Neoplasms, Experimental | 1 | 2020 | 115 | 0.180 |
Why?
| Carcinoma, Papillary | 1 | 2020 | 65 | 0.180 |
Why?
| Carcinoma, Transitional Cell | 1 | 2020 | 54 | 0.180 |
Why?
| Pregnancy in Diabetics | 1 | 2020 | 25 | 0.180 |
Why?
| Carcinoma, Signet Ring Cell | 1 | 2019 | 14 | 0.180 |
Why?
| Pregnancy Complications, Neoplastic | 1 | 2019 | 21 | 0.180 |
Why?
| Carcinoma, Lewis Lung | 1 | 2019 | 11 | 0.180 |
Why?
| Placenta Diseases | 1 | 2019 | 12 | 0.180 |
Why?
| DNA Mutational Analysis | 2 | 2018 | 217 | 0.180 |
Why?
| Colonic Neoplasms | 1 | 2021 | 164 | 0.180 |
Why?
| Radiotherapy | 1 | 2020 | 138 | 0.180 |
Why?
| Hepatic Veno-Occlusive Disease | 1 | 2019 | 10 | 0.180 |
Why?
| Carcinoma, Renal Cell | 2 | 2018 | 120 | 0.170 |
Why?
| DNA Polymerase II | 1 | 2019 | 10 | 0.170 |
Why?
| Hodgkin Disease | 1 | 2019 | 51 | 0.170 |
Why?
| DNA Mismatch Repair | 1 | 2019 | 17 | 0.170 |
Why?
| Premature Birth | 1 | 2021 | 154 | 0.170 |
Why?
| Dermatology | 1 | 2020 | 72 | 0.170 |
Why?
| Melanoma, Experimental | 1 | 2019 | 49 | 0.170 |
Why?
| Fetal Diseases | 1 | 2019 | 54 | 0.170 |
Why?
| Odds Ratio | 3 | 2015 | 604 | 0.170 |
Why?
| Skin Diseases | 1 | 2020 | 141 | 0.170 |
Why?
| T-Lymphocytes | 1 | 2021 | 373 | 0.170 |
Why?
| Monocytes | 1 | 2019 | 156 | 0.170 |
Why?
| Metformin | 1 | 2020 | 66 | 0.170 |
Why?
| Sarcoma | 1 | 2020 | 73 | 0.170 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2019 | 116 | 0.170 |
Why?
| Inflammation | 2 | 2020 | 674 | 0.170 |
Why?
| Urinary Bladder Neoplasms | 1 | 2020 | 173 | 0.170 |
Why?
| Methionine Adenosyltransferase | 1 | 2018 | 20 | 0.170 |
Why?
| Pregnancy | 7 | 2021 | 2620 | 0.170 |
Why?
| Reproducibility of Results | 4 | 2017 | 1304 | 0.160 |
Why?
| Mice, Inbred C57BL | 5 | 2024 | 1999 | 0.160 |
Why?
| Radiation Tolerance | 1 | 2019 | 86 | 0.160 |
Why?
| DNA Helicases | 1 | 2020 | 132 | 0.160 |
Why?
| Hypoglycemic Agents | 1 | 2020 | 177 | 0.160 |
Why?
| Rhabdomyosarcoma | 1 | 2018 | 13 | 0.160 |
Why?
| Neural Cell Adhesion Molecule L1 | 1 | 2017 | 2 | 0.160 |
Why?
| Nuclear Proteins | 1 | 2020 | 252 | 0.160 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2018 | 40 | 0.160 |
Why?
| Logistic Models | 3 | 2015 | 995 | 0.160 |
Why?
| Pathology, Molecular | 1 | 2017 | 24 | 0.160 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 69 | 0.160 |
Why?
| Hepatocytes | 1 | 2019 | 214 | 0.150 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 62 | 0.150 |
Why?
| Disease Models, Animal | 6 | 2020 | 1639 | 0.150 |
Why?
| Intestinal Mucosa | 2 | 2020 | 259 | 0.150 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2019 | 434 | 0.150 |
Why?
| Biopsy | 5 | 2020 | 692 | 0.150 |
Why?
| Osteosarcoma | 1 | 2017 | 37 | 0.150 |
Why?
| Pregnancy Complications | 1 | 2021 | 384 | 0.150 |
Why?
| Vimentin | 1 | 2016 | 33 | 0.140 |
Why?
| Neoplastic Cells, Circulating | 1 | 2017 | 93 | 0.140 |
Why?
| Papillomaviridae | 1 | 2017 | 107 | 0.140 |
Why?
| DNA-Binding Proteins | 2 | 2016 | 462 | 0.140 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2017 | 474 | 0.140 |
Why?
| Gene Expression Profiling | 2 | 2019 | 1138 | 0.140 |
Why?
| Cadherins | 1 | 2016 | 72 | 0.140 |
Why?
| Viral Load | 1 | 2016 | 85 | 0.140 |
Why?
| Acetaminophen | 1 | 2019 | 349 | 0.140 |
Why?
| Time Factors | 3 | 2021 | 3213 | 0.140 |
Why?
| Hepatocyte Nuclear Factor 1-beta | 1 | 2015 | 4 | 0.130 |
Why?
| Neoplasms, Muscle Tissue | 1 | 2015 | 13 | 0.130 |
Why?
| Malate Dehydrogenase | 1 | 2014 | 11 | 0.130 |
Why?
| Classification | 1 | 2015 | 15 | 0.130 |
Why?
| Colposcopy | 1 | 2015 | 19 | 0.130 |
Why?
| Lipogenesis | 1 | 2014 | 34 | 0.130 |
Why?
| Skin Neoplasms | 1 | 2020 | 532 | 0.130 |
Why?
| World Health Organization | 1 | 2015 | 56 | 0.130 |
Why?
| Cytosol | 1 | 2014 | 101 | 0.130 |
Why?
| Mice, Inbred BALB C | 3 | 2021 | 368 | 0.120 |
Why?
| Neoplasm, Residual | 1 | 2015 | 166 | 0.120 |
Why?
| Flow Cytometry | 1 | 2017 | 546 | 0.120 |
Why?
| Mammary Neoplasms, Experimental | 1 | 2015 | 135 | 0.120 |
Why?
| Histones | 1 | 2016 | 335 | 0.120 |
Why?
| Multiple Myeloma | 1 | 2009 | 3035 | 0.120 |
Why?
| High-Throughput Nucleotide Sequencing | 3 | 2021 | 206 | 0.120 |
Why?
| Oncogenes | 1 | 2013 | 63 | 0.120 |
Why?
| Antineoplastic Agents | 2 | 2021 | 1300 | 0.110 |
Why?
| Gastrointestinal Tract | 1 | 2014 | 135 | 0.110 |
Why?
| Clusterin | 1 | 2012 | 6 | 0.110 |
Why?
| Patient Selection | 1 | 2015 | 286 | 0.110 |
Why?
| Cell Line, Tumor | 4 | 2020 | 1550 | 0.110 |
Why?
| Intestines | 1 | 2014 | 204 | 0.110 |
Why?
| Membrane Proteins | 1 | 2015 | 389 | 0.110 |
Why?
| Predictive Value of Tests | 4 | 2018 | 1048 | 0.110 |
Why?
| Histocytochemistry | 1 | 2012 | 46 | 0.110 |
Why?
| Liver | 2 | 2019 | 1225 | 0.110 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2012 | 25 | 0.110 |
Why?
| Pancreatic Neoplasms | 1 | 2015 | 234 | 0.110 |
Why?
| Strongyloidiasis | 1 | 2012 | 9 | 0.110 |
Why?
| Risk Factors | 3 | 2015 | 3935 | 0.110 |
Why?
| Cytomegalovirus Infections | 1 | 2012 | 46 | 0.100 |
Why?
| Prednisone | 1 | 2012 | 111 | 0.100 |
Why?
| Follow-Up Studies | 2 | 2016 | 2387 | 0.100 |
Why?
| Tissue Inhibitor of Metalloproteinases | 1 | 2011 | 11 | 0.100 |
Why?
| Treatment Outcome | 3 | 2021 | 5604 | 0.100 |
Why?
| Teratoma | 1 | 2011 | 24 | 0.100 |
Why?
| Matrix Metalloproteinases | 1 | 2011 | 52 | 0.100 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2012 | 230 | 0.100 |
Why?
| Adenoma, Oxyphilic | 1 | 2010 | 17 | 0.100 |
Why?
| Male | 9 | 2020 | 27334 | 0.100 |
Why?
| Sensitivity and Specificity | 3 | 2020 | 923 | 0.100 |
Why?
| Image Processing, Computer-Assisted | 1 | 2012 | 256 | 0.100 |
Why?
| Adolescent | 3 | 2020 | 6897 | 0.090 |
Why?
| Phenotype | 3 | 2019 | 820 | 0.090 |
Why?
| Tissue Array Analysis | 3 | 2015 | 50 | 0.090 |
Why?
| Glucocorticoids | 1 | 2012 | 234 | 0.090 |
Why?
| Tumor Cells, Cultured | 2 | 2021 | 477 | 0.090 |
Why?
| Epigenesis, Genetic | 1 | 2012 | 399 | 0.090 |
Why?
| Pregnancy Outcome | 2 | 2021 | 249 | 0.090 |
Why?
| Infant, Newborn | 3 | 2021 | 2907 | 0.080 |
Why?
| Telemedicine | 1 | 2015 | 449 | 0.080 |
Why?
| Pilot Projects | 2 | 2023 | 808 | 0.080 |
Why?
| Hysterectomy | 2 | 2021 | 88 | 0.080 |
Why?
| Cell Differentiation | 2 | 2024 | 720 | 0.080 |
Why?
| Cell Nucleus | 2 | 2021 | 203 | 0.080 |
Why?
| Societies, Medical | 2 | 2019 | 194 | 0.080 |
Why?
| Host-Pathogen Interactions | 2 | 2021 | 143 | 0.080 |
Why?
| Consensus | 2 | 2020 | 157 | 0.070 |
Why?
| Ventricular Pressure | 1 | 2006 | 19 | 0.070 |
Why?
| Neoplasms | 1 | 2017 | 1316 | 0.070 |
Why?
| Isoproterenol | 1 | 2006 | 52 | 0.070 |
Why?
| Gene Expression Regulation | 3 | 2023 | 1062 | 0.070 |
Why?
| Terminology as Topic | 2 | 2018 | 72 | 0.070 |
Why?
| Serum Response Factor | 1 | 2006 | 41 | 0.070 |
Why?
| Kaplan-Meier Estimate | 2 | 2018 | 514 | 0.070 |
Why?
| Combined Modality Therapy | 2 | 2020 | 692 | 0.070 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 2 | 2016 | 17 | 0.070 |
Why?
| Practice Guidelines as Topic | 2 | 2019 | 492 | 0.070 |
Why?
| Kidney | 1 | 2010 | 820 | 0.070 |
Why?
| Neoplasm Metastasis | 2 | 2018 | 252 | 0.070 |
Why?
| Cytokines | 2 | 2020 | 676 | 0.060 |
Why?
| Proportional Hazards Models | 2 | 2017 | 431 | 0.060 |
Why?
| Chromatography, Liquid | 2 | 2016 | 243 | 0.060 |
Why?
| Cells, Cultured | 2 | 2021 | 1737 | 0.060 |
Why?
| Tandem Mass Spectrometry | 2 | 2016 | 248 | 0.060 |
Why?
| Th1 Cells | 1 | 2024 | 50 | 0.060 |
Why?
| Heart | 1 | 2006 | 360 | 0.060 |
Why?
| Dose-Response Relationship, Drug | 2 | 2019 | 1476 | 0.060 |
Why?
| Interleukin-10 | 1 | 2024 | 107 | 0.060 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 866 | 0.060 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2023 | 85 | 0.060 |
Why?
| Choriocarcinoma | 2 | 2012 | 7 | 0.050 |
Why?
| Genes, T-Cell Receptor | 1 | 2021 | 5 | 0.050 |
Why?
| Uterine Hemorrhage | 1 | 2021 | 11 | 0.050 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 2021 | 30 | 0.050 |
Why?
| Parturition | 1 | 2021 | 54 | 0.050 |
Why?
| Phthalazines | 1 | 2021 | 19 | 0.050 |
Why?
| Remission Induction | 1 | 2021 | 221 | 0.050 |
Why?
| Quinazolines | 1 | 2021 | 39 | 0.050 |
Why?
| Vulva | 1 | 2020 | 18 | 0.050 |
Why?
| Taurine | 1 | 2020 | 16 | 0.050 |
Why?
| Research Report | 1 | 2020 | 16 | 0.050 |
Why?
| Lymphocyte Activation | 1 | 2021 | 197 | 0.050 |
Why?
| Herb-Drug Interactions | 1 | 2020 | 30 | 0.050 |
Why?
| Metabolic Networks and Pathways | 1 | 2021 | 104 | 0.050 |
Why?
| Mucin-2 | 1 | 2020 | 9 | 0.050 |
Why?
| Toxicity Tests | 1 | 2020 | 52 | 0.050 |
Why?
| Alkaline Phosphatase | 1 | 2020 | 99 | 0.050 |
Why?
| Molecular Targeted Therapy | 1 | 2021 | 128 | 0.050 |
Why?
| Risk | 1 | 2021 | 343 | 0.050 |
Why?
| Piperazines | 1 | 2021 | 116 | 0.050 |
Why?
| Chorionic Villi | 1 | 2019 | 3 | 0.050 |
Why?
| Chemokines | 1 | 2020 | 96 | 0.050 |
Why?
| Birth Weight | 1 | 2020 | 126 | 0.050 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2020 | 40 | 0.050 |
Why?
| Preoperative Period | 1 | 2020 | 59 | 0.050 |
Why?
| Receptors, Progesterone | 1 | 2020 | 57 | 0.040 |
Why?
| Endothelium | 1 | 2019 | 45 | 0.040 |
Why?
| Ultrasonography, Doppler, Color | 1 | 2019 | 35 | 0.040 |
Why?
| Pyrimidines | 1 | 2021 | 196 | 0.040 |
Why?
| Colon | 1 | 2020 | 110 | 0.040 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2019 | 75 | 0.040 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 673 | 0.040 |
Why?
| United States | 3 | 2016 | 5217 | 0.040 |
Why?
| Chest Pain | 1 | 2019 | 65 | 0.040 |
Why?
| Glutamine | 1 | 2020 | 168 | 0.040 |
Why?
| Cytochrome P-450 Enzyme System | 1 | 2020 | 192 | 0.040 |
Why?
| Dyspnea | 1 | 2019 | 78 | 0.040 |
Why?
| Liver Function Tests | 1 | 2019 | 43 | 0.040 |
Why?
| Estrogen Receptor alpha | 1 | 2020 | 95 | 0.040 |
Why?
| Mice, Transgenic | 2 | 2014 | 656 | 0.040 |
Why?
| Fatal Outcome | 1 | 2019 | 225 | 0.040 |
Why?
| Mice, Inbred Strains | 1 | 2019 | 198 | 0.040 |
Why?
| Drug Synergism | 1 | 2019 | 171 | 0.040 |
Why?
| Gestational Age | 1 | 2020 | 435 | 0.040 |
Why?
| Imaging, Three-Dimensional | 1 | 2019 | 171 | 0.040 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2019 | 219 | 0.040 |
Why?
| Mice, Nude | 1 | 2019 | 283 | 0.040 |
Why?
| Wolffian Ducts | 1 | 2018 | 1 | 0.040 |
Why?
| Mullerian Ducts | 1 | 2018 | 4 | 0.040 |
Why?
| Nephrectomy | 1 | 2018 | 93 | 0.040 |
Why?
| Mutation Rate | 1 | 2018 | 40 | 0.040 |
Why?
| Lymph Node Excision | 1 | 2019 | 140 | 0.040 |
Why?
| Cell Lineage | 1 | 2018 | 93 | 0.040 |
Why?
| Mixed Tumor, Mullerian | 1 | 2017 | 3 | 0.040 |
Why?
| Ultrasonography, Prenatal | 1 | 2019 | 177 | 0.040 |
Why?
| DNA Copy Number Variations | 1 | 2018 | 114 | 0.040 |
Why?
| Anal Canal | 1 | 2017 | 23 | 0.040 |
Why?
| Skin | 1 | 2020 | 469 | 0.040 |
Why?
| Matrix Attachment Region Binding Proteins | 1 | 2017 | 31 | 0.040 |
Why?
| Dietary Supplements | 1 | 2020 | 449 | 0.040 |
Why?
| Telomerase | 1 | 2016 | 30 | 0.040 |
Why?
| Disease-Free Survival | 1 | 2017 | 485 | 0.040 |
Why?
| Macrophages | 1 | 2019 | 405 | 0.040 |
Why?
| Transcriptome | 1 | 2019 | 346 | 0.040 |
Why?
| Lymph Nodes | 1 | 2019 | 284 | 0.040 |
Why?
| Vaccines, Subunit | 1 | 2016 | 20 | 0.040 |
Why?
| Ontario | 1 | 2016 | 50 | 0.040 |
Why?
| Mesonephros | 1 | 2016 | 1 | 0.040 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2016 | 85 | 0.030 |
Why?
| Diet | 1 | 2020 | 598 | 0.030 |
Why?
| Antiporters | 1 | 2015 | 19 | 0.030 |
Why?
| Extracellular Fluid | 1 | 2015 | 19 | 0.030 |
Why?
| Anion Exchange Protein 1, Erythrocyte | 1 | 2015 | 15 | 0.030 |
Why?
| Signal Transduction | 1 | 2023 | 1753 | 0.030 |
Why?
| Leukocytes, Mononuclear | 1 | 2016 | 133 | 0.030 |
Why?
| S100 Proteins | 1 | 2015 | 41 | 0.030 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 79 | 0.030 |
Why?
| Cell Hypoxia | 1 | 2015 | 87 | 0.030 |
Why?
| Pressure | 1 | 2015 | 120 | 0.030 |
Why?
| Cell Count | 1 | 2015 | 181 | 0.030 |
Why?
| Blood Vessels | 1 | 2015 | 78 | 0.030 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 52 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2015 | 158 | 0.030 |
Why?
| Random Allocation | 1 | 2015 | 312 | 0.030 |
Why?
| Radiotherapy Dosage | 1 | 2015 | 243 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2014 | 165 | 0.030 |
Why?
| Genetic Predisposition to Disease | 1 | 2018 | 570 | 0.030 |
Why?
| Proteome | 1 | 2016 | 178 | 0.030 |
Why?
| Prospective Studies | 1 | 2020 | 2604 | 0.030 |
Why?
| Likelihood Functions | 1 | 2014 | 61 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 206 | 0.030 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2015 | 278 | 0.030 |
Why?
| Vaccination | 1 | 2016 | 294 | 0.030 |
Why?
| Genes, erbB-1 | 1 | 2013 | 9 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2015 | 643 | 0.030 |
Why?
| Apoptosis | 1 | 2020 | 1300 | 0.030 |
Why?
| Gene Frequency | 1 | 2013 | 120 | 0.030 |
Why?
| Lipid Metabolism | 1 | 2014 | 194 | 0.030 |
Why?
| Anti-Bacterial Agents | 1 | 2019 | 820 | 0.030 |
Why?
| SEER Program | 1 | 2013 | 91 | 0.030 |
Why?
| Adiposity | 1 | 2014 | 142 | 0.030 |
Why?
| Mesentery | 1 | 2012 | 36 | 0.030 |
Why?
| Rural Health Services | 1 | 2015 | 175 | 0.030 |
Why?
| Communication | 1 | 2015 | 273 | 0.030 |
Why?
| Diet, High-Fat | 1 | 2014 | 216 | 0.030 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 153 | 0.030 |
Why?
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2012 | 5 | 0.030 |
Why?
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 7 | 0.030 |
Why?
| Pregnancy Proteins | 1 | 2012 | 8 | 0.030 |
Why?
| Angiopoietin-2 | 1 | 2012 | 16 | 0.030 |
Why?
| Angiopoietin-1 | 1 | 2012 | 18 | 0.030 |
Why?
| Ovary | 1 | 2012 | 105 | 0.030 |
Why?
| Ivermectin | 1 | 2012 | 8 | 0.030 |
Why?
| Neoplasms, Glandular and Epithelial | 1 | 2012 | 48 | 0.030 |
Why?
| Research Design | 1 | 2015 | 374 | 0.030 |
Why?
| Antiparasitic Agents | 1 | 2012 | 9 | 0.030 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2012 | 37 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2015 | 642 | 0.030 |
Why?
| Insulin Resistance | 1 | 2014 | 300 | 0.030 |
Why?
| Hydatidiform Mole | 1 | 2011 | 1 | 0.030 |
Why?
| Infant | 1 | 2020 | 3817 | 0.030 |
Why?
| Algorithms | 1 | 2015 | 697 | 0.020 |
Why?
| Crohn Disease | 1 | 2012 | 96 | 0.020 |
Why?
| RNA, Messenger | 1 | 2014 | 1202 | 0.020 |
Why?
| Isoenzymes | 1 | 2011 | 177 | 0.020 |
Why?
| Interleukin-6 | 1 | 2012 | 315 | 0.020 |
Why?
| Necrosis | 1 | 2010 | 208 | 0.020 |
Why?
| Promoter Regions, Genetic | 1 | 2012 | 520 | 0.020 |
Why?
| Gene Expression | 1 | 2012 | 664 | 0.020 |
Why?
| Radiography | 1 | 2011 | 524 | 0.020 |
Why?
| Risk Assessment | 1 | 2015 | 1361 | 0.020 |
Why?
| Cell Line | 1 | 2012 | 1153 | 0.020 |
Why?
| Cohort Studies | 1 | 2013 | 1543 | 0.020 |
Why?
| DNA Methylation | 1 | 2012 | 574 | 0.020 |
Why?
| Rats | 1 | 2014 | 3415 | 0.020 |
Why?
| Blotting, Western | 1 | 2006 | 683 | 0.020 |
Why?
| Myocardium | 1 | 2006 | 441 | 0.010 |
Why?
| Age Factors | 1 | 2006 | 1198 | 0.010 |
Why?
| Child | 1 | 2011 | 7341 | 0.010 |
Why?
|
|
Quick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|